A Phase 4 interventional study of TAP (transversus abdominis plane block) and QL (quadratus lumborum block) in Cesarean Section, Pain Management and Neuropathic Pain, sponsored by Michał Borys. Completed at 1 site in Poland. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-28.
Sponsored by Michał Borys · Phase 4, Interventional, and Treatment
Comparison of two types of analgesia after cesarean section.
All patients will anaesthetised with spinal technique. Ultrasound-guided transversus abdominis plane or quadratus lumborum block to treat postoperative pain. Postoperative pain will measured with visual-analogue scale (VAS). 1, 2, 6 months after surgery each patient will be called to assess neuropathic pain with Neuropathic Pain Symptom Inventory (NPSI).
Written consent will be obtained before the cesarean section. Only subarachnoidally anaesthetised patients may participate in the study. Pencil-point spinal needle and bupivacaine (Marcaine Heavy Spinal 0.5 %) will be used.
At the end of surgery ultrasound-guided regional block will be performed. Each patient will be randomly allocated to one of the treated group: transversus abdominis plane block (TAP) or quadratus lumborum (QL). Patients receive 0.2 mL of local anesthetic solution (0.25 % bupivacaine) on each side.
Postoperative pain will be measured with VAS (visual-analogue scale) 2, 4, 8, 12 and 24 hours after the end of operation.
Paracetamol, metamizol, ketoprofen may be given as required. Whenever pain exceeds 40 (VAS) 5 mg of morphine will be given intravenously (maximum two dosages per day).
1, 3, 6 months patients will be called to assess neuropathic pain. Neuropathic Pain Symptom Inventory (NPSI) will be used.
1,287 studies on the registry are indexed under Neuralgia; 256 are open to participants now.
This study's enrollment of 232 is above the median of 52 across 973 interventional studies indexed under Neuralgia.
Browse Neuralgia studies →This is the only study on the registry with Michał Borys as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Ultrasound-guided transversus abdominis plane block at the end of cesarean section
Procedure: TAP (transversus abdominis plane block) · Drug: Bupivacaine · Device: Needle · Drug: Paracetamol · Drug: Metamizol · Drug: Ketoprofen · Drug: Morphine
Ultrasound-guided quadratus lumborum block at the end of cesarean section
Procedure: QL (quadratus lumborum block) · Drug: Bupivacaine · Device: Needle · Drug: Paracetamol · Drug: Metamizol · Drug: Ketoprofen · Drug: Morphine
ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
ultrasound-guided regional block between abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
In both groups (TAP\&QL) 0.25% bupivacaine will be given (0.2 mL/kg)
Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
Postoperative pain measured with VAS
Acute pain measured with VAS (visual-analogue scale).
Time frame: up to 24 hours after surgery
Neuropathic pain assessed with NPSI
Neuropathic pain occurrence with Neuropathic Pain Symptom Inventory (NPSI)
Time frame: 6 months from the surgery
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.